Karyopharm Therapeutics | KPTI - DEBITO





DEBITO Cambiamento Data
AbbVie USD 72.86B 5.36B 2026-03
Abbott USD 34.05B 20.19B 2026-03
Amgen USD 57.32B 2.72B 2026-03
AstraZeneca USD 32.24B 1.68B 2026-06
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Eli Lilly USD 43.37B 867M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Incyte USD 38.27M 1.16M 2026-06
J&J USD 54.99B 7.05B 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 36.51M 500K 2026-03
Merck USD 49.12B 222M 2026-03
Nektar Therapeutics USD 0 0 2022-06
Novartis USD 49.01B 2.02B 2026-06
Novartis USD 47B 14.98B 2026-03
Pfizer USD 63.19B 536M 2026-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.94T 58.13B 2026-06
Tectonic Therapeutic USD 876K 115K 2024-12
TG Therapeutics USD 754.44M 884K 2026-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Xencor USD 175.16M 12.58M 2026-03